GSK has confirmed a plan to spin off its consumer healthcare division into a separate company, Haleon. GSK owns 68% of Haleon, of which 80% will be distributed to GSK shareholders. The new company will own a portfolio of drugs such as Sensodyne, Voltaren, Panadol and Centrum. Haleon shares will begin trading on the LSE on July 18, 2022.